FTRE · NASDAQ
Fortrea Holdings Inc.
$23.06 -2.83 (-10.93%)
Company overview
Fortrea Holdings Inc., a contract research organization, primarily engages in the provision of biopharmaceutical product and medical device development services worldwide. It operates through two segments: Clinical Services and Enabling Services. The Clinical Services segment provides services across the clinical pharmacology and clinical development spectrum. The Enabling Services segment provides patient access and clinical trial technology solutions that streamline complex randomization and optimize the trial drug supply process. The company offers delivery models that include full service, functional service provider, and hybrid service structures. It also offers Phase I-IV clinical trial management, differentiated technology-enabled trial solutions, and post-approval services. The company serves pharmaceutical, biotechnology, and medical device organizations. Fortrea Holdings Inc.
- Sector
- Healthcare
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Market cap
- $2.2B
- Employees
- 15,000
- Headquarters
- Durham, NC
- Website
- fortrea.com
- CEO
- Anshul Thakral
- Listed
- June 20, 2023
- P/E
- -4.67
- Dividend yield
- 0.00%
Company financials
- Revenue
- $2.7B
- Gross profit
- $433M
- Operating income
- -$14.7M
- EBITDA
- -$284M
- Net income
- -$447M
- EPS
- -$4.93
- Total assets
- $2.7B
- Total debt
- $75.4M
- Gross margin
- 15.97%
- Net margin
- -16.50%
- Earnings yield
- -21.41%
Showing FY 2025
FTRE
1D
NASDAQ
O24.36H26.16L24.30C25.88+1.45 (+5.94%)Vol3.59M